H. Evin Gulbahce
No Rating Available
(Learn About Our Rating System)

H. Evin Gulbahce, MD, MSCI

Languages spoken: English

Dr. Gulbahce is a professor of pathology at the University of Utah School of Medicine. She received her MD from Hacettepe University in Ankara, Turkey, and completed a residency in anatomic and clinical pathology and a surgical pathology fellowship at the University of Minnesota. Her research interests include HER2 testing, and breast cancer risk factors, specifically risk factor for basal-like and triple negative cancers.

Specialties

  • Pathology, Anatomical

Dr. Gulbahce is a professor of pathology at the University of Utah School of Medicine. She received her MD from Hacettepe University in Ankara, Turkey, and completed a residency in anatomic and clinical pathology and a surgical pathology fellowship at the University of Minnesota. Her research interests include HER2 testing, and breast cancer risk factors, specifically risk factor for basal-like and triple negative cancers.

Board Certification and Academic Information

Academic Departments Pathology -Professor

Education history

Professional Medical Medicine - Hacettepe University School of Medicine M.D.
Residency Anatomic and Clinical Pathology - University of Minnesota Resident
Fellowship Surgical Pathology - University of Minnesota Fellow
Graduate Training Clinical Investigation - University of Utah M.S.C.I

Selected Publications

Journal Article

  1. Lin L, Sirohi D, Coleman JF, Gulbahce H (2019). American Society of Clinical Oncology/College of American Pathologists 2018 Focused Update of Breast Cancer HER2 FISH Testing GuidelinesResults From a National Reference Laboratory. American journal of clinical pathology, 152(4), 479-485.
  2. Gulbahce HE, Downs-Kelly E, Herget KA, Stoddard G (2021). The 21-Gene Recurrence Score in Special Histologic Subtypes of Breast Cancer: A Population-Based Study. Archives of pathology & laboratory medicine, 146, 478-484.
  3. Jedrzkiewicz J, Sirohi D, Uvejzovic N, Gulbahce H (2021). RAI1 alternate probe identifies additional gastroesophageal adenocarcinoma cases as amplified following equivocal HER2 fluorescence in situ hybridization testing: experience from a national reference laboratory. Modern pathology, 35, 549-553.
  4. Mahlow J, Goold EA, Jedrzkiewicz J, Gulbahce H (2021). What to Expect From the New ASCO/CAP Guideline Recommendations for Hormone Receptor Testing in Breast Cancer: A National Reference Laboratory Experience. Applied immunohistochemistry & molecular morphology, 29(4), 245-250.
  5. Gulbahce HE, White S, Herget KA, Stoddard G, Camp NJ, Buys SS, Sweeney (2021). 21-gene recurrence score testing utilization among older women from different races: A population-based study. Journal of geriatric oncology, 12(2), 206-211.
  6. Wilcock DM, Sirohi D, Coleman JF, Gulbahce H (2022). Digital imaging correlation of immunohistochemistry and fluorescence in situ hybridization in breast carcinoma cases with HER2 genetic heterogeneity. Human pathology, 126, 129-135.
  7. Gulbahce H (2017). Impact of 2013 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2 Fluorescent In Situ Hybridization Testing in Breast Cancers : Experience From a National Reference Laboratory. American journal of clinical pathology, 148(4), 308-313.
  8. Gulbahce HE, Blair CK, Sweeney C, Salama M (2017). Quantification of Estrogen Receptor Expression in Normal Breast Tissue in Postmenopausal Women With Breast Cancer and Association With Tumor Subtypes. Applied immunohistochemistry & molecular morphology, 25(8), 548-552.
  9. Geiersbach KB, Willmore-Payne C, Pasi AV, Paxton CN, Werner TL, Xu X, Wittwer CT, Gulbahce HE, Downs-Kelly (2016). Genomic Copy Number Analysis of HER2-Equivocal Breast Cancers. American journal of clinical pathology, 146(4), 439-47.
  10. Witt BL, Albertson DJ, Coppin MG, Horrocks CF, Post M, Gulbahce H (2015). Use of in situ hybridization for HPV in head and neck tumors: experience from a national reference laboratory. Head and neck pathology, 9(1), 60-4.
  11. Gulbahce HE, Sweeney C, Surowiecka M, Knapp D, Varghese L, Blair C (2013). Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors. Human pathology, 44(11), 2427-31.
  12. Wilcock D, Sirohi D, Albertson D, Cleary AS, Coleman JF, Jedrzkiewicz J, Mahlow J, Ruano AL, Gulbahce H (2023). Clinicopathologic Features of Breast Carcinoma With 2018 American Society of Clinical Oncology/College of American Pathologists Fluorescence In Situ Hybridization Group 3 (Human Epidermal Growth Factor Receptor 2 Chromosome 17 Centromere Ratio <2.0 and Average Human Epidermal Growth Factor Receptor 2 Copy Number ¿6.0) Breast Cancers. Archives of pathology & laboratory medicine, 148(8), 890-897.
  13. McMurtry V, Cleary AS, Ruano AL, Lomo L, Gulbahce H (2023). Metaplastic Breast Carcinoma: Clinicopathologic Features and Recurrence Score Results From a Population-based Database. American journal of clinical oncology, 46(12), 559-566.
  14. Wilcock DM, Moore KH, Rowe L, Mahlow J, Jedrzkiewicz J, Cleary AS, Lomo L, Ruano AL, Gering M, Bradshaw D, Maughan M, Tran P, Burlingame J, Davis R, Affolter K, Albertson DJ, Adelhardt P, Kim JT, Coleman JF, Deftereos G, Gulbahce EH, Sirohi (2023). Quantitative Imaging Analysis Fluorescence In Situ Hybridization Validation for Clinical HER2 Testing in Breast Cancer. Archives of pathology & laboratory medicine,
  15. Wilcock DM, McMurtry V, Coleman JF, Kim JT, Khalili P, Deftereos G, Albertson D, Gulbahce EH, Liu T, Sirohi (2022). Histopathological Correlation of Chromosome 12 Polysomy by Fluorescence in Situ Hybridization in Adipocytic Neoplasms. International journal of surgical pathology, 30(7), 734-742.
  16. Willmore-Payne C, Damjanovich-Colmenares K, Pasi AV, Werner TL, Gulbahce HE, Downs-Kelly E, Geiersbach K (2016). Inconsistent Results With Different Secondary Reflex Assays for Resolving HER2 Status. American journal of clinical pathology, 146(5), 618-626.
  17. Beckman JD, Belcher JD, Vineyard JV, Chen C, Nguyen J, Nwaneri MO, O'Sullivan MG, Gulbahce E, Hebbel RP, Vercellotti G (2009). Inhaled carbon monoxide reduces leukocytosis in a murine model of sickle cell disease. American journal of physiology. Heart and circulatory physiology, 297(4), H1243-53.
  18. Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, Nelson MT, Emory TH, Tuttle TM, Yee D, Garwood (2004). Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T. Radiology, 233(2), 424-31.
  19. Stewart RL, Caron JE, Gulbahce EH, Factor RE, Geiersbach KB, Downs-Kelly (2017). HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features. Modern pathology, 30(11), 1561-1566.
  20. Oktay MF, Cureoglu S, Schachern PA, Gulbahce E, Paparella MM, Hayasi (2006). Histologic changes in the anterior mallear ligament and the head of the malleus in otosclerosis. Otolaryngology--head and neck surgery, 134(2), 232-5.
  21. Hart C, Opperman DA, Gulbahce E, Adams (2006). Branchial cleft cyst: a rare diagnosis in a 91-year-old patient. Otolaryngology--head and neck surgery, 135(6), 955-7.
  22. Johnson ED, Gulbahce E, McNally J, Buys S (2016). Malignant Phyllodes Tumor Presenting in Bone, Brain, Lungs, and Lymph Nodes. Case reports in oncology, 9(3), 861-868.
  23. Schneider F, Jin Y, Van Smaalen K, Gulbahce EH, Factor RE, Li (2019). The FDA-Approved Breast Cancer HER2 Evaluation Kit (HercepTest; Dako) May Miss Some HER2-Positive Breast Cancers. American journal of clinical pathology, 151(5), 504-510.
  24. Singh C, Manivel JC, Truskinovsky AM, Savik K, Amirouche S, Holler J, Thyagarajan B, Gulbahce HE, Pambuccian S (2014). Variability of pathologists' utilization of p16 and ki-67 immunostaining in the diagnosis of cervical biopsies in routine pathology practice and its impact on the frequencies of cervical intraepithelial neoplasia diagnoses and cytohistologic correlations. Archives of pathology & laboratory medicine, 138(1), 76-87.
  25. Hui L, Geiersbach KB, Downs-Kelly E, Gulbahce H (2017). RAI1 Alternate Probe Identifies Additional Breast Cancer Cases as Amplified Following Equivocal HER2 Fluorescence In Situ Hybridization Testing: Experience From a National Reference Laboratory. Archives of pathology & laboratory medicine, 141(2), 274-278.
  26. Ward KA, Ecker PM, White RR, Melnik TE, Gulbahce EH, Wilke MS, Sangueza O (2010). Papillary intralymphatic angioendothelioma of the thigh: A case report and review of the literature. Dermatology online journal, 16(4), 4.
  27. Woodard JP, Gulbahce E, Shreve M, Steiner M, Peters C, Hite S, Ramsay NK, DeFor T, Baker K (2000). Pulmonary cytolytic thrombi: a newly recognized complication of stem cell transplantation. Bone marrow transplantation, 25(3), 293-300.
  28. Smith AR, Gulbahce E, Burke MJ, Cao Q, Macmillan ML, Tolar J, Orchard PJ, Blazar BR, Baker KS, Wagner JE, Verneris M (2011). Lower leukemia relapse in pediatric patients with pulmonary cytolytic thrombi following allogeneic transplant. Bone marrow transplantation, 46(3), 368-71.
  29. Gulbahce HE, Bernard PS, Weltzien EK, Factor RE, Kushi LH, Caan BJ, Sweeney (2018). Differences in molecular features of triple-negative breast cancers based on the age at diagnosis. Cancer, 124(24), 4676-4684.
  30. Vaklavas C, Matsen CB, Chu Z, Boucher KM, Scherer SD, Pathi S, Beck A, Brownson KE, Buys SS, Chittoria N, D'Astous E, Gulbahce HE, Henry NL, Kimani S, Porretta J, Rosenthal R, Ward J, Wei M, Welm BE, Welm A (2024). TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer. JCO precision oncology, 8, e2300724.
  31. Wilcock DM, Zhao J, Gulbahce H (2025). Resolving HER2 status in breast carcinoma patients with complete deletion of CEP17 in fluorescence in-situ hybridization assays. Cancer genetics, 296-297, 196-199.
  32. Wilcock D, Sirohi D, Coleman JF, Adelhardt P, Kim JT, Albertson D, Affolter K, Beech C, Jedrzkiewicz J, Ruano AL, Cleary AS, Mahlow J, Balatico M, Gulbahce H (2025). HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry. American journal of clinical pathology, 163(6), 837-846.

Review

  1. Downs E, Gulbahce H (2024). "Lobular lesions of the breast: From the classic to the variants". Seminars in diagnostic pathology, 41(6), 258-271.

Case Report

  1. Johnson ED, Downs-Kelly E, Bull DA, Gulbahce H (2017). Primary Cystic Pleuropulmonary Synovial Sarcoma Presenting as Recurrent Pneumothorax. Case reports in oncology, 10(2), 660-665.

Letter

  1. Gulbahce HE, Coleman JF, Sirohi (2019). Interference of Tissue-Marking Dyes With Fluorescence In Situ Hybridization Assays. Archives of pathology & laboratory medicine, 143(11), 1299.
  2. Gulbahce HE, Factor R, Geiersbach K, Downs-Kelly (2016). HER2 Immunohistochemistry-Guided Targeted Fluorescence In Situ Hybridization Analysis Does Not Help Identify Intratumoral Heterogeneity in Breast Cancer. Archives of pathology & laboratory medicine, 140(8), 741.
  3. Balatico M, Ruano AL, Cleary AS, Lomo L, Gulbahce H (2024). Male Invasive Lobular Breast Cancer: Clinicopathologic Features Including Recurrence Score Results From a Population-Based Database. (Letter to the Editor). Archives of pathology & laboratory medicine, 148(3), 263-264.

Other

  1. Wilcock DM, Zhao J, Gulbahce H (2025). Corrigendum to "Resolving HER2 status in breast carcinoma patients with complete deletion of CEP17 in fluorescence in-situ hybridization assays" [Cancer Genetics, 296-297, 2025, 196-199]. Cancer genetics, 296-297, 217.